Asia Green Biotechnology

Asia Green Biotechnology Current Assets

Delisted·Sep 23, 2026

Current Assets of Asia Green Biotechnology (ASIA.CN) as of Nov 15, 2026.

Current Assets

0.00CAD

Last updated:

Current Assets of Asia Green Biotechnology is 2023 0.00 CAD. Current Assets of Asia Green Biotechnology was 2022 0.00 CAD. It decreases by % lower compared to the previous year.

The Asia Green Biotechnology Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
19,962.00 CAD
Jan 1, 2019
0.00 CAD
Jan 1, 2020
32,775.00 CAD
Jan 1, 2021
0.00 CAD
Jan 1, 2022
0.00 CAD
Jan 1, 2023
0.00 CAD
The Asia Green Biotechnology Current Assets history
YEARCurrent AssetsYoY
0.00CAD—
0.00CAD—
0.00CAD-100.00%
32,775.00CAD—
0.00CAD-100.00%
19,962.00CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Asia Green Biotechnology Stock analysis

What does Asia Green Biotechnology do? Asia Green Biotechnology Corp develops and supplies proprietary organic hybridization technology for agri-technology applications. The company partners with InPlanta Biotechnology Inc. for hemp cultivation under a license agreement, and collaborates with Swysh Inc. and Pathway Rx Corp for cannabinoid extract development. Revenue is generated through the supply of technology and related products, with operations expanding in Cambodia and Thailand through R&D programs. The firm focuses on commercial hemp and cannabinoid product development under licensed agreements. The company's primary market segments include agricultural technology providers and medicinal cannabinoid extract buyers. InPlanta Biotechnology Inc. licenses hemp cultivation, while Swysh Inc. and Pathway Rx Corp. license cannabinoid extract development. Asia Green Biotechnology Corp. supplies technology and manages the commercialization of these products derived from its organic hybridization technology. Asia Green Biotechnology Corp. operates under license agreements with InPlanta Biotechnology Inc., Swysh Inc., and Pathway Rx Corp. to develop and supply hemp and cannabinoid products. The company's revenue streams come from technology supply and product commercialization under these agreements, with R&D programs in Cambodia and Thailand supporting future market expansion. Asia Green Biotechnology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Asia Green Biotechnology stock

On Eulerpool you can find the complete historical development of Current Assets Asia Green Biotechnology since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Asia Green Biotechnology historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Asia Green Biotechnology

All Key Metrics — Asia Green Biotechnology